MEDI 3506

Drug Profile

MEDI 3506

Alternative Names: MEDI3506

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 30 Apr 2018 MedImmune re-initiates a phase I trial in Chronic obstructive pulmonary disease in United Kingdom (SC) (IV) (NCT03096795)
  • 22 Jan 2018 MedImmune terminates a phase I trial in Chronic obstructive pulmonary disease in United Kingdom since its pending for protocol amendment (NCT03096795)
  • 15 May 2017 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (SC and IV) (NCT03096795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top